1. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study;Gyawali;BMJ,2021
2. Issues in using progression-free survival when evaluating oncology products;Fleming;J Clin Oncol,2009
3. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials;Driscoll;Cancer J,2009
4. The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges;Huang;Lancet Reg Health West Pac,2023
5. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review;Beaver;JAMA Oncol,2018